Disclaimer:
Medidex is not a provider of medical services and all information is provided for the convenience of the user. No medical decisions should be made based on the information provided on this website without first consulting a licensed healthcare provider.This website is intended for persons 18 years or older. No person under 18 should consult this website without the permission of a parent or guardian.
Hypaque Sodium
Overview
What is Hypaque Sodium?
HYPAQUE meglumine, brand of diatrizoate meglumine, is a water-soluble, radiopaque diagnostic medium. It is a triiodinated benzoic acid derivative containing 47.06 percent organically bound iodine. It is constituted as an iodinated anion (diatrizoate) and a radiolucent cation (meglumine).
HYPAQUE meglumine 60 percent (w/v) is a sterile aqueous solution containing 60 g of the meglumine salt of diatrizoic acid per 100 mL of solution. The solution is a clear-colorless to pale yellow liquid, and the pH is adjusted between 6.5 and 7.7 with diatrizoic acid or meglumine solution. It is a relatively thermostable solution and may be autoclaved without harmful effects, although it should be protected from strong light. The 60 percent solution contains edetate calcium disodium 1:10,000 as a sequestering stabilizing agent. Each 1 mL contains approximately 282 mg of organically bound iodine. The viscosity of the solution is 6.17 cp at 25°C and 4.12 cp at 37°C.
It is hypertonic to blood with an osmolality of 1415 mosm/kg (determined by VPO). A 13 percent solution (w/v) is isotonic.
It is a colorless, microcrystalline solid which is readily soluble in water.
It is meglumine 3,5-diacetamido-2,4,6-triiodobenzoate (CHINO • CHNO) with a molecular weight of 809.13, and has the following structural formula:
What does Hypaque Sodium look like?
What are the available doses of Hypaque Sodium?
Sorry No records found.
What should I talk to my health care provider before I take Hypaque Sodium?
Sorry No records found
How should I use Hypaque Sodium?
THE FOLLOWING SECTIONS FOR INDIVIDUAL INDICATIONS AND USAGE CONTAIN CONTRAINDICATIONS, WARNINGS, PRECAUTIONS, ADVERSE REACTIONS, AND DOSAGE AND ADMINISTRATION SECTIONS RELATED TO THE . HOWEVER, IT SHOULD BE UNDERSTOOD THAT THE INFORMATION IN THE SECTIONS IS ALSO LIKELY TO APPLY TO ALL OF THESE SPECIFIC USES.
Hydration
Preparation of the patient will vary with preference of the radiologist and the type of radiological procedure performed. Specific radiographic procedures used will depend on the state of the patient and the diagnostic indications. Individual dose should be tailored according to age, body size, and indication for examination. (See section for specific Dosage and Administration.)
Solutions of radiopaque diagnostic agents for intravascular use should be at body temperature when injected and may need to be warmed before use. In the event that crystallization occurs, the solution may be clarified by placing the vial in a water bath at 40°C to 50°C and shaking it gently for two to three minutes or until the solids redissolve. If the particles still persist, do not use this vial but discard it. The solution should be protected from light and any unused portion remaining in the container should be discarded.
Dilution and withdrawal of the contrast agents should be accomplished under aseptic conditions with sterile syringes.
Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration. Avoid contaminating catheters, syringes, needles, and contrast media with glove powder or cotton fibers.
What interacts with Hypaque Sodium?
Sorry No Records found
What are the warnings of Hypaque Sodium?
SEVERE ADVERSE EVENTS—INADVERTENT INTRATHECAL ADMINISTRATION
Serious adverse reactions have been reported due to the inadvertent intrathecal administration of iodinated contrast media that are not indicated for intrathecal use. These serious adverse reactions include: death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. Special attention must be given to insure that this drug product is not administered intrathecally.
Ionic iodinated contrast media inhibit blood coagulation, , more than nonionic contrast media. Nonetheless, it is prudent to avoid prolonged contact of blood with syringes containing ionic contrast media.
Serious, rarely fatal, thromboembolic events causing myocardial infarction and stroke have been reported during angiographic procedures with both ionic and nonionic contrast media. Therefore, meticulous intravascular administration technique is necessary, particularly during angiographic procedures, to minimize thromboembolic events. Numerous factors, including length of procedure, catheter and syringe material, underlying disease state and concomitant medications may contribute to the development of thromboembolic events. For these reasons, meticulous angiographic techniques are recommended including close attention to guidewire and catheter manipulation, use of manifold systems and/or three-way stopcocks, frequent catheter flushing with heparinized saline solutions and minimizing the length of the procedure. The use of plastic syringes in place of glass syringes has been reported to decrease but not eliminate the likelihood of clotting.
Excretory urography is potentially hazardous in patients with multiple myeloma. In some of those patients, therapeutically resistant anuria resulting in progressive uremia, renal failure and eventually death has followed this procedure. Although neither the contrast agent nor dehydration has been proved separately to be the cause of anuria in myelomatous patients, it has been speculated that the combination of both may be causative. The risk of excretory urography in myelomatous patients is not a contraindication to the procedure; however, they require special precautions. Partial dehydration in the preparation of these patients for the examination is not recommended since this may predispose to the precipitation of myeloma protein in the renal tubules. Myeloma, which occurs most commonly in persons over age 40, should be considered before instituting urographic procedures.
Contrast media may promote sickling in individuals who are homozygous for sickle cell disease when the material is injected intravenously or intra-arterially.
Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution. If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risks, the procedures may be performed; however, the amount of radiopaque medium injected should be kept to an absolute minimum. The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.
Recent reports of thyroid storm occurring following the intravascular use of iodinated radiopaque diagnostic agents in patients with hyperthyroidism or with an autonomously functioning thyroid nodule suggest that this additional risk be evaluated in such patients before use of HYPAQUE meglumine.
Contrast media administered for cardiac catheterization and angiocardiography may cause cellular injury to circulating lymphocytes. Chromosomal damage in humans includes inhibition of mitosis, increases in the number of micronuclei, and chromosome aberrations. The damages appear to be related to the contrast medium itself rather than to the x-ray radiation. It is to be noted that those agents have not been adequately tested in animal or laboratory systems.
Urography should be performed with caution in patients with severely impaired renal function and patients with combined renal and hepatic disease.
Subcutaneous extravasation, chiefly because of hypertonic cellulitis, causes transitory stinging. If the volume extravasated is small, ill effects are very unlikely. However, if the extravasation is extensive especially in poorly vascularized areas (eg, dorsum of the foot or hand), and especially in the presence of vascular disease, skin slough may occur. Injection of sterile water to dilute or addition of spreading agents to speed absorption have not been successful and may aggravate the condition.
Selective spinal arteriography or arteriography of trunks providing spinal branches can cause mild to severe muscle spasm. However, serious neurologic sequelae, including permanent paralysis, have occasionally been reported. (See also .)
In patients with subarachnoid hemorrhage, a rare association between contrast administration and clinical deterioration, including convulsions and death, has been reported. Therefore, administration of intravascular iodinated ionic contrast media in these patients should be undertaken with caution.
What are the precautions of Hypaque Sodium?
Diagnostic procedures which involve the use of radiopaque diagnostic agents should be carried out under the direction of personnel with the prerequisite training and with a thorough knowledge of the particular procedure to be performed. Appropriate facilities should be available for coping with any complication of the procedure, as well as for emergency treatment of severe reactions to the contrast agent itself. After parenteral administration of a radiopaque agent, competent personnel and emergency facilities should be available for at least 30 to 60 minutes since severe delayed reactions have occurred (see ).
The possibility of a reaction, including serious, life-threatening, fatal, anaphylactic or cardiovascular reactions should always be considered (see ). It is of utmost importance that a course of action be carefully planned in advance for immediate treatment of serious reactions, and that adequate and appropriate personnel be readily available in case of any reaction.
Preparatory dehydration for angiography and CT procedures is unnecessary and may be dangerous, contributing to acute renal failure in infants, young children, the elderly, patients with preexisting renal insufficiency, patients with advanced vascular disease, and diabetic patients. Dehydration in these patients seems to be enhanced by the osmotic diuretic action of urographic agents. Overnight fluid retention for urography may be undesirable and is considered unnecessary when using this relatively high (60%) concentration.
Although azotemia is not a contraindication, the medium should be used with great care in patients with advanced renal destruction associated with severe uremia. (See also ).
Acute renal failure has been reported in diabetic patients with diabetic nephropathy and in susceptible nondiabetic patients (often elderly with preexisting renal disease) following excretory urography. Therefore, careful consideration of the potential risks should be given before performing this radiographic procedure in these patients. (See also, .)
Immediately following surgery, excretory urography should be used with caution in renal transplant recipients.
The possibility of an idiosyncratic reaction in susceptible patients should always be considered (see ). The susceptible population includes patients with a history of a previous reaction to a contrast medium, patients with a known sensitivity to iodine per se, and patients with a known clinical hypersensitivity: bronchial asthma, hay fever, and food allergies.
The occurrence of severe idiosyncratic reactions has prompted the use of several pretesting methods. However, pretesting cannot be relied upon to predict severe reactions and may itself be hazardous for the patient. It is suggested that a thorough medical history with emphasis on allergy and hypersensitivity, prior to injection of any contrast media, may be more accurate than pretesting in predicting potential adverse reactions.
A positive history of allergies or hypersensitivity does not arbitrarily contraindicate the use of a contrast agent, where a diagnostic procedure is thought essential, but caution should be exercised (see ). Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions in such patients should be considered. Recent reports indicate that such pretreatment does not prevent serious life-threatening reactions, but may reduce both their incidence and severity.
Due to the transitory increase in the circulatory osmotic load, injections of urographic agents should be used with caution in patients with congestive heart failure. Such patients should be observed for several hours following the procedure to detect delayed hemodynamic disturbances.
General anesthesia may be indicated in the performance of some procedures in young or uncooperative children and in selected adult patients; however, a higher incidence of adverse reactions has been reported in these patients, and may be attributable to the inability of the patient to identify untoward symptoms, or to the hypotensive effect of anesthesia which can reduce cardiac output and increase the duration of exposure to the contrast agent.
Seizure activity is rare (about 0.01%) on intravenous injection of ionic contrast media. However, in the higher doses used for CT in patients with brain metastases the incidence can be much higher (1% to 10%). In these patients prophylactic use of a small parenteral dose of diazepam is suggested immediately before injection when extra high dose CT regimens are employed.
In addition to the general precautions already described, excretory urography, cholangiography, and other uses also have hazards associated with the particular techniques employed. (See section.)
Information for Patients
Patients receiving injectable radiopaque diagnostic agents should be instructed to:
Drug Interactions
Renal toxicity has been reported in a few patients with liver dysfunction who were given oral cholecystographic agents followed by urographic agents. Administration of intravascular urographic agents should therefore be postponed in any patient with a known or suspected hepatic or biliary disorder who has recently received a cholecystographic contrast agent.
Addition of an inotropic agent to contrast agents may produce a paradoxical depressant response which can be deleterious to the ischemic myocardium.
Diphenhydramine hydrochloride may cause precipitation when mixed in the same syringe with HYPAQUE meglumine 60%.
Under certain circumstances (pH, temperature, concentrations, time), diatrizoate solutions are incompatible with promethazine hydrochloride, diphenhydramine hydrochloride, brompheniramine maleate, or papaverine hydrochloride solutions.
Do not prefill plastic syringes with HYPAQUE meglumine 60% for prolonged periods (ie, for several hours or longer) before use.
Drug/Laboratory Test Interactions
If any of these studies, which might be affected by contrast media are indicated, it is recommended that they be performed prior to administration of the contrast medium or two or more days afterwards.
Diatrizoate salts interfere with several laboratory urine and blood tests.
Coagulation:
Platelet aggregation:
Serum calcium:
Red cell counts:
Leukocyte counts:
Urea nitrogen (BUN):
Serum creatinine:
Contrast media which are excreted in the urine, may interfere with some laboratory determinations eg, proteinuria, specific gravity, osmolality, or bacterial cultures.
Protein-bound iodine (PBI) and total serum organic iodine: Transient increase of both tests following urography have been noticed. The results of PBI and radioactive iodine uptake studies which depend on iodine estimations will not accurately reflect thyroid function for up to 16 days following administration of iodinated urographic media. However, thyroid function tests not depending on iodine estimations, eg, T resin uptake or free thyroxine assays are not affected.
Carcinogenesis, Mutagenesis, Impairment of Fertility
Long-term studies in animals have not been performed in order to evaluate carcinogenic potential, mutagenesis, or whether HYPAQUE meglumine 60 percent can affect fertility in males or females.
Pregnancy Category C
Animal reproduction studies have not been conducted with HYPAQUE meglumine 60 percent. It is also not known whether HYPAQUE meglumine 60 percent can cause fetal harm when administered to a pregnant woman or can affect reproduction capacity. HYPAQUE meglumine 60 percent should be given to a pregnant woman only if clearly needed. Doses up to 2500 mg/kg in rats, given IV daily, administered during gestation days 6 to 15 revealed no teratogenic abnormalities.
Labor and Delivery
It is not known whether use of these contrast agents during labor or delivery has immediate or delayed adverse effects on the fetus, prolongs the duration of labor or increases the likelihood that forceps delivery or other obstetrical intervention or resuscitation of the newborn will be necessary.
Nursing Mothers
Diatrizoate salts are excreted unchanged in human milk. Because of the potential adverse reactions, although it has not been established that serious adverse reactions occur in nursing infants, caution should be exercised when these intravascular contrast media are administered to a nursing woman.
Pediatric Use
Infants and small children should not have any fluid restriction prior to excretory urography or any other procedures (see ). Guidelines for pediatric dosages are presented in .
What are the side effects of Hypaque Sodium?
Approximately 95 percent of adverse reactions accompanying the intravascular use of diatrizoate salts are of mild to moderate severity. However, life-threatening reactions and fatalities, mostly of cardiovascular origin, have occurred.
Adverse reactions to injectable contrast media fall into two categories: chemotoxic reactions and idiosyncratic reactions.
Chemotoxic reactions result from the physicochemical properties of the contrast media, the dose, and the speed of injection. All hemodynamic disturbances and injuries to organs or vessels perfused by the contrast medium are included in this category.
Idiosyncratic reactions include all other reactions. They occur more frequently in patients 20 to 40 years old. Idiosyncratic reactions may or may not be dependent on the amount of dose injected, the speed of injection, the mode of injection, and the radiographic procedure. Idiosyncratic reactions are subdivided into minor, intermediate, and severe. The minor reactions are self-limited and of short duration; the severe reactions are life-threatening and treatment is urgent and mandatory.
The reported incidence of adverse reactions to contrast media in patients with a history of allergy are twice that of the general population. Patients with a history of previous reactions to a contrast medium are three times more susceptible than other patients. However, sensitivity to contrast media does not appear to increase with repeated examinations.
Most adverse reactions to injectable contrast media appear within one to three minutes after the start of injection, but delayed reactions may occur.
Adverse reactions are grouped by organ system and listed below by decreasing order of occurrence and with an approximate incidence of occurrence. Significantly more severe reactions are listed before the other reactions regardless of frequency.
Greater Than 1 in 100 Patients
Body as a Whole:
Isolated reports of hypotensive collapse and shock following urography are found in the literature.
The incidence of shock is estimated to occur in 1 out of 20,000 (0.005 percent) patients.
Cardiovascular System:
Digestive System:
Nervous System:
Respiratory System:
Skin and Appendages:
Pain at the injection site is estimated to occur in about 12 percent of the patients undergoing
urography. Pain is usually due to extravasation.
Painful hot erythematous swelling above the venipuncture site was estimated to occur in more than
one percent of the patients undergoing phlebography.
Special Senses:
Urogenital System:
Less Than 1 in 100 Patients
Other infrequently reported reactions without accompanying incidence rates are listed below, grouped by organ system.
Body as a Whole:
Cardiovascular System:
Digestive System:
Nervous System:
Respiratory System:
Skin and Appendages:
Special Senses:
Urogenital:
What should I look out for while using Hypaque Sodium?
HYPAQUE meglumine 60 percent has no absolute contraindications in its recommended uses (see general and ).
Do not use HYPAQUE meglumine 60 percent solution for myelography or for examination of dorsal cysts or sinuses which might communicate with the subarachnoid space.
Urography and large dose vascular procedures are contraindicated in dehydrated azotemic patients. (See also .)
What might happen if I take too much Hypaque Sodium?
At dosage levels of 1 mL/lb, the incidence of unpleasant side effects increases. At total dosage of 2 mL/lb, administered over a short period of time (eg, 30 minutes), clinical signs of systemic intolerance appear (mostly related to hyperosmolar effects) and are manifest as tremors, irritability, and tachycardia. Above these maximal tolerated dosage levels in otherwise healthy adults, an increasing incidence and severity of dyspnea and pulmonary edema should be expected.
Four cases of overdosage in infants, during urography, are reported. Three of the infants died within 19 hours of the injection. The overdose ranged from slightly above the recommended pediatric dosage to a dose exceeding 19 g/kg. The symptoms of overdosage appeared between 10 minutes to several hours after injection of the contrast medium. Adverse effects were life-threatening, affecting mainly the pulmonary and cardiovascular systems. The symptoms included: cyanosis, bradycardia, acidosis, pulmonary hemorrhage, convulsions, coma, and cardiac arrest. All infants showed a poor visualization of the kidneys and a diffuse opacification of all the tissues and vasculature. Autopsy findings showed acute pulmonary damage and/or edema of subcutaneous tissues. Treatment of an overdose of injectable radiopaque contrast media is directed toward the support of all vital functions, and prompt institution of symptomatic therapy.
The acute intravenous LD of diatrizoate meglumine in mice is equivalent in iodine content of 5.3 gI/kg to 8.0 gI/kg and seem to be directly proportional to the rate of injection.
Diatrizoate meglumine is dialyzable.
How should I store and handle Hypaque Sodium?
Store at controlled room temperature 20° to 25°C (68° to 77°F)Rx onlyManufactured by:Yung Shin Pharmaceutical Industrial Co., Ltd.Tachia, TaichungTaiwan, ROCRevision: April 2007Store at controlled room temperature 20° to 25°C (68° to 77°F)Rx onlyManufactured by:Yung Shin Pharmaceutical Industrial Co., Ltd.Tachia, TaichungTaiwan, ROCRevision: April 2007Store at controlled room temperature 20° to 25°C (68° to 77°F)Rx onlyManufactured by:Yung Shin Pharmaceutical Industrial Co., Ltd.Tachia, TaichungTaiwan, ROCRevision: April 2007Store at controlled room temperature 20° to 25°C (68° to 77°F)Rx onlyManufactured by:Yung Shin Pharmaceutical Industrial Co., Ltd.Tachia, TaichungTaiwan, ROCRevision: April 2007Store at controlled room temperature 20° to 25°C (68° to 77°F)Rx onlyManufactured by:Yung Shin Pharmaceutical Industrial Co., Ltd.Tachia, TaichungTaiwan, ROCRevision: April 2007Vials of 50 mL, rubber stoppered, box of 25 (NDC 0407-0746-04).Vials of 100 mL, rubber stoppered, box of 10 (NDC 0407-0747-02).Box of 10 calibrated 200 mL dilution bottles with hangers containing 150 mL HYPAQUE meglumine 60%; rubber stoppered (NDC 0407-0749-20).Box of 10 calibrated 200 mL dilution bottles with hangers containing 200 mL HYPAQUE meglumine 60%; rubber stoppered (NDC 0407-0750-10).Protect from light.Vials of 50 mL, rubber stoppered, box of 25 (NDC 0407-0746-04).Vials of 100 mL, rubber stoppered, box of 10 (NDC 0407-0747-02).Box of 10 calibrated 200 mL dilution bottles with hangers containing 150 mL HYPAQUE meglumine 60%; rubber stoppered (NDC 0407-0749-20).Box of 10 calibrated 200 mL dilution bottles with hangers containing 200 mL HYPAQUE meglumine 60%; rubber stoppered (NDC 0407-0750-10).Protect from light.Vials of 50 mL, rubber stoppered, box of 25 (NDC 0407-0746-04).Vials of 100 mL, rubber stoppered, box of 10 (NDC 0407-0747-02).Box of 10 calibrated 200 mL dilution bottles with hangers containing 150 mL HYPAQUE meglumine 60%; rubber stoppered (NDC 0407-0749-20).Box of 10 calibrated 200 mL dilution bottles with hangers containing 200 mL HYPAQUE meglumine 60%; rubber stoppered (NDC 0407-0750-10).Protect from light.Vials of 50 mL, rubber stoppered, box of 25 (NDC 0407-0746-04).Vials of 100 mL, rubber stoppered, box of 10 (NDC 0407-0747-02).Box of 10 calibrated 200 mL dilution bottles with hangers containing 150 mL HYPAQUE meglumine 60%; rubber stoppered (NDC 0407-0749-20).Box of 10 calibrated 200 mL dilution bottles with hangers containing 200 mL HYPAQUE meglumine 60%; rubber stoppered (NDC 0407-0750-10).Protect from light.Vials of 50 mL, rubber stoppered, box of 25 (NDC 0407-0746-04).Vials of 100 mL, rubber stoppered, box of 10 (NDC 0407-0747-02).Box of 10 calibrated 200 mL dilution bottles with hangers containing 150 mL HYPAQUE meglumine 60%; rubber stoppered (NDC 0407-0749-20).Box of 10 calibrated 200 mL dilution bottles with hangers containing 200 mL HYPAQUE meglumine 60%; rubber stoppered (NDC 0407-0750-10).Protect from light.
Clinical Information
Chemical Structure
No Image foundClinical Pharmacology
HYPAQUE meglumine 60 percent can be administered as an intravenous bolus for brain tissue enhancement using computerized tomography. Increased tissue contrast differential for the scan is achieved either because of increased vascular (arterial, venous, or capillary bed) contrast or by blood brain barrier penetration of the medium (or its absence) in certain localized areas of disrupted vascular permeability. The degree of tissue enhancement caused by increased blood contrast is directly related to blood iodine content. However, the degree of enhancement due to extravascular accumulation of iodine resulting from blood brain barrier disruption will depend on the extent of disruption, the blood level of iodine, and the time delay prior to scanning. The nature of the pathology will determine whether an immediate or delayed scan is optimal.
Non-Clinical Toxicology
HYPAQUE meglumine 60 percent has no absolute contraindications in its recommended uses (see general and ).Do not use HYPAQUE meglumine 60 percent solution for myelography or for examination of dorsal cysts or sinuses which might communicate with the subarachnoid space.
Urography and large dose vascular procedures are contraindicated in dehydrated azotemic patients. (See also .)
Renal toxicity has been reported in a few patients with liver dysfunction who were given oral cholecystographic agents followed by urographic agents. Administration of intravascular urographic agents should therefore be postponed in any patient with a known or suspected hepatic or biliary disorder who has recently received a cholecystographic contrast agent.
Addition of an inotropic agent to contrast agents may produce a paradoxical depressant response which can be deleterious to the ischemic myocardium.
Diphenhydramine hydrochloride may cause precipitation when mixed in the same syringe with HYPAQUE meglumine 60%.
Under certain circumstances (pH, temperature, concentrations, time), diatrizoate solutions are incompatible with promethazine hydrochloride, diphenhydramine hydrochloride, brompheniramine maleate, or papaverine hydrochloride solutions.
Do not prefill plastic syringes with HYPAQUE meglumine 60% for prolonged periods (ie, for several hours or longer) before use.
Diagnostic procedures which involve the use of radiopaque diagnostic agents should be carried out under the direction of personnel with the prerequisite training and with a thorough knowledge of the particular procedure to be performed. Appropriate facilities should be available for coping with any complication of the procedure, as well as for emergency treatment of severe reactions to the contrast agent itself. After parenteral administration of a radiopaque agent, competent personnel and emergency facilities should be available for at least 30 to 60 minutes since severe delayed reactions have occurred (see ).
The possibility of a reaction, including serious, life-threatening, fatal, anaphylactic or cardiovascular reactions should always be considered (see ). It is of utmost importance that a course of action be carefully planned in advance for immediate treatment of serious reactions, and that adequate and appropriate personnel be readily available in case of any reaction.
Preparatory dehydration for angiography and CT procedures is unnecessary and may be dangerous, contributing to acute renal failure in infants, young children, the elderly, patients with preexisting renal insufficiency, patients with advanced vascular disease, and diabetic patients. Dehydration in these patients seems to be enhanced by the osmotic diuretic action of urographic agents. Overnight fluid retention for urography may be undesirable and is considered unnecessary when using this relatively high (60%) concentration.
Although azotemia is not a contraindication, the medium should be used with great care in patients with advanced renal destruction associated with severe uremia. (See also ).
Acute renal failure has been reported in diabetic patients with diabetic nephropathy and in susceptible nondiabetic patients (often elderly with preexisting renal disease) following excretory urography. Therefore, careful consideration of the potential risks should be given before performing this radiographic procedure in these patients. (See also, .)
Immediately following surgery, excretory urography should be used with caution in renal transplant recipients.
The possibility of an idiosyncratic reaction in susceptible patients should always be considered (see ). The susceptible population includes patients with a history of a previous reaction to a contrast medium, patients with a known sensitivity to iodine per se, and patients with a known clinical hypersensitivity: bronchial asthma, hay fever, and food allergies.
The occurrence of severe idiosyncratic reactions has prompted the use of several pretesting methods. However, pretesting cannot be relied upon to predict severe reactions and may itself be hazardous for the patient. It is suggested that a thorough medical history with emphasis on allergy and hypersensitivity, prior to injection of any contrast media, may be more accurate than pretesting in predicting potential adverse reactions.
A positive history of allergies or hypersensitivity does not arbitrarily contraindicate the use of a contrast agent, where a diagnostic procedure is thought essential, but caution should be exercised (see ). Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions in such patients should be considered. Recent reports indicate that such pretreatment does not prevent serious life-threatening reactions, but may reduce both their incidence and severity.
Due to the transitory increase in the circulatory osmotic load, injections of urographic agents should be used with caution in patients with congestive heart failure. Such patients should be observed for several hours following the procedure to detect delayed hemodynamic disturbances.
General anesthesia may be indicated in the performance of some procedures in young or uncooperative children and in selected adult patients; however, a higher incidence of adverse reactions has been reported in these patients, and may be attributable to the inability of the patient to identify untoward symptoms, or to the hypotensive effect of anesthesia which can reduce cardiac output and increase the duration of exposure to the contrast agent.
Seizure activity is rare (about 0.01%) on intravenous injection of ionic contrast media. However, in the higher doses used for CT in patients with brain metastases the incidence can be much higher (1% to 10%). In these patients prophylactic use of a small parenteral dose of diazepam is suggested immediately before injection when extra high dose CT regimens are employed.
In addition to the general precautions already described, excretory urography, cholangiography, and other uses also have hazards associated with the particular techniques employed. (See section.)
Approximately 95 percent of adverse reactions accompanying the intravascular use of diatrizoate salts are of mild to moderate severity. However, life-threatening reactions and fatalities, mostly of cardiovascular origin, have occurred.
Adverse reactions to injectable contrast media fall into two categories: chemotoxic reactions and idiosyncratic reactions.
Chemotoxic reactions result from the physicochemical properties of the contrast media, the dose, and the speed of injection. All hemodynamic disturbances and injuries to organs or vessels perfused by the contrast medium are included in this category.
Idiosyncratic reactions include all other reactions. They occur more frequently in patients 20 to 40 years old. Idiosyncratic reactions may or may not be dependent on the amount of dose injected, the speed of injection, the mode of injection, and the radiographic procedure. Idiosyncratic reactions are subdivided into minor, intermediate, and severe. The minor reactions are self-limited and of short duration; the severe reactions are life-threatening and treatment is urgent and mandatory.
The reported incidence of adverse reactions to contrast media in patients with a history of allergy are twice that of the general population. Patients with a history of previous reactions to a contrast medium are three times more susceptible than other patients. However, sensitivity to contrast media does not appear to increase with repeated examinations.
Most adverse reactions to injectable contrast media appear within one to three minutes after the start of injection, but delayed reactions may occur.
Adverse reactions are grouped by organ system and listed below by decreasing order of occurrence and with an approximate incidence of occurrence. Significantly more severe reactions are listed before the other reactions regardless of frequency.
Reference
This information is obtained from the National Institute of Health's Standard Packaging Label drug database.
"https://dailymed.nlm.nih.gov/dailymed/"
While we update our database periodically, we cannot guarantee it is always updated to the latest version.
Review
Read user comments about the side effects, benefits, and effectiveness of losartan oral.
Overall User Ratings
516Total User Reviews
User Reviews
Learn about
User Reviews
Professional
Clonazepam Description Each single-scored tablet, for oral administration, contains 0.5 mg, 1 mg, or 2 mg Clonazepam, USP, a benzodiazepine. Each tablet also contains corn starch, lactose monohydrate, magnesium stearate, microcrystalline cellulose, and povidone. Clonazepam tablets USP 0.5 mg contain Yellow D&C No. 10 Aluminum Lake. Clonazepam tablets USP 1 mg contain Yellow D&C No. 10 Aluminum Lake, as well as FD&C Blue No. 1 Aluminum Lake. Chemically, Clonazepam, USP is 5-(o-chlorophenyl)-1,3-dihydro-7-nitro-2H-1,4-benzodiazepin-2-one. It is a light yellow crystalline powder. It has the following structural formula: C15H10ClN3O3 M.W. 315.72Tips
Tips
Interactions
Interactions
A total of 440 drugs (1549 brand and generic names) are known to interact with Imbruvica (ibrutinib). 228 major drug interactions (854 brand and generic names) 210 moderate drug interactions (691 brand and generic names) 2 minor drug interactions (4 brand and generic names) Show all medications in the database that may interact with Imbruvica (ibrutinib).